Vivaldi Biosciences Inc.
This article was originally published in Start Up
Vivaldi Biosciences is developing live attenuated vaccines with altered NS1, a gene critical to viral survival. The company's lead product is a seasonal influenza vaccine and it has early-stage programs in pandemic flu. Vivaldi views these flu projects as proof of concept that might enable broader applications in the hands of a larger company.
You may also be interested in...
Marinomed Biotechnologie, which derives drugs from marine sources, is eyeing both the OTC and prescription markets. The Vienna-based start-up has already launched its first product: an OTC nasal spray formulation of a drug based on a polysaccharide extracted from seaweed. The company has in vitro and in vivo efficacy data for this compound against seasonal influenza, suggesting that it may also have potential for treating pandemic flu.
The swine flu/H1N1 pandemic presents a lucrative opportunity for drug developers and Big Pharmas won't be the only firms to capitalize on the sudden multibillion-dollar opportunity. There's evidence that the pandemic is driving investors to flu-focused biotechs as well. In this issue, we profile four emerging companies that hope to reap the rewards of what should continue to be a promising fund-raising environment for potentially novel flu therapies.
Alios BioPharma aims to create an improved version of interferon--the only drug that could be considered a broad-spectrum antiviral--to help patients who do not respond well to currently marketed forms of the protein. Alios also plans to develop a small-molecule drug that can be given orally yet carry out a key function of the interferon response-degrading viral genomes. Such a drug could potentially treat influenza, hepatitis C and B, HIV, and a host of other viruses.